KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Accumulated Expenses (2016 - 2026)

TherapeuticsMD filings provide 15 years of Accumulated Expenses readings, the most recent being $2.2 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 1627.91% to $2.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.2 million, a 1627.91% increase, with the full-year FY2025 number at $1.7 million, down 18.15% from a year prior.
  • Accumulated Expenses hit $2.2 million in Q1 2026 for TherapeuticsMD, up from $1.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.1 million in Q4 2023 to a low of $129000.0 in Q1 2025.
  • Median Accumulated Expenses over the past 4 years was $2.0 million (2025), compared with a mean of $1.9 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 32.11% in 2024 and later skyrocketed 1627.91% in 2026.
  • TherapeuticsMD's Accumulated Expenses stood at $3.1 million in 2023, then crashed by 32.11% to $2.1 million in 2024, then fell by 18.15% to $1.7 million in 2025, then grew by 28.03% to $2.2 million in 2026.
  • The last three reported values for Accumulated Expenses were $2.2 million (Q1 2026), $1.7 million (Q4 2025), and $2.0 million (Q3 2025) per Business Quant data.